Chemokines and matrix metalloproteinase-9 in leukocyte recruitment to the central nervous system
- PMID: 12909304
- DOI: 10.1016/s0361-9230(03)00097-2
Chemokines and matrix metalloproteinase-9 in leukocyte recruitment to the central nervous system
Abstract
Chemokines and matrix metalloproteinases (MMPs) play key roles in leukocyte migration across the blood-brain barrier (BBB) in infectious and inflammatory diseases, including multiple sclerosis (MS). In MS some chemokine receptors are expressed by an increased percentage of T cells in blood, the CSF concentration of chemokine ligands for these receptors is increased, and there is accumulation of T cells expressing relevant chemokine receptors in CSF and in the CNS parenchyma. Chemokine receptor expression patterns appear to reflect disease activity and disease stage in MS. MMPs are constitutively expressed or induced by proinflammatory cytokines and chemokines in leukocytes and CNS-resident cells. Several MMPs are expressed in MS plaques, and the CSF concentration of MMP-9 is increased in MS. The CSF concentration of MMP-9 may reflect disease activity in MS, and the CSF concentration of MMP-9 is higher in patients carrying the MS-associated HLA type DRB1 1501. We review how chemokines and MMP-9 may be involved in the pathogenesis of MS by controlling leukocyte migration between different functional compartments. Measuring expression of these molecules may find use as surrogate markers of disease activity in MS, and interfering with their function holds promise as a novel therapeutic strategy in MS.
Similar articles
-
Chemokine-based therapies for MS: how do we get there from here?Trends Immunol. 2001 Nov;22(11):591-3. doi: 10.1016/s1471-4906(01)02056-7. Trends Immunol. 2001. PMID: 11698200
-
Focal MMP-2 and MMP-9 activity at the blood-brain barrier promotes chemokine-induced leukocyte migration.Cell Rep. 2015 Feb 24;10(7):1040-54. doi: 10.1016/j.celrep.2015.01.037. Epub 2015 Feb 19. Cell Rep. 2015. PMID: 25704809
-
Expression of the beta-chemokine receptors CCR2, CCR3 and CCR5 in multiple sclerosis central nervous system tissue.J Neuroimmunol. 2000 Aug 1;108(1-2):192-200. doi: 10.1016/s0165-5728(00)00274-5. J Neuroimmunol. 2000. PMID: 10900353
-
Therapeutic Targeting of Chemokines and Chemokine Receptors in Multiple Sclerosis: Opportunities and Challenges.CNS Neurol Disord Drug Targets. 2018;17(7):496-508. doi: 10.2174/1871527317666180713111100. CNS Neurol Disord Drug Targets. 2018. PMID: 30003862 Review.
-
Inflammatory cell trafficking across the blood-brain barrier: chemokine regulation and in vitro models.Immunol Rev. 2012 Jul;248(1):228-39. doi: 10.1111/j.1600-065X.2012.01127.x. Immunol Rev. 2012. PMID: 22725965 Free PMC article. Review.
Cited by
-
Permeability of the blood-brain barrier predicts conversion from optic neuritis to multiple sclerosis.Brain. 2015 Sep;138(Pt 9):2571-83. doi: 10.1093/brain/awv203. Epub 2015 Jul 17. Brain. 2015. PMID: 26187333 Free PMC article.
-
Optic neuritis: chemokine receptor CXCR3 and its ligands.Br J Ophthalmol. 2004 Sep;88(9):1146-8. doi: 10.1136/bjo.2003.040980. Br J Ophthalmol. 2004. PMID: 15317705 Free PMC article.
-
Correlation of matrix metalloproteinase 3 and matrix metalloproteinase 9 levels with non-motor symptoms in patients with Parkinson's disease.Front Aging Neurosci. 2022 Aug 22;14:889257. doi: 10.3389/fnagi.2022.889257. eCollection 2022. Front Aging Neurosci. 2022. PMID: 36072482 Free PMC article.
-
[Update on pathophysiologic and immunotherapeutic approaches for the treatment of multiple sclerosis].Nervenarzt. 2007 Aug;78(8):883-911. doi: 10.1007/s00115-007-2261-9. Nervenarzt. 2007. PMID: 17551708 Review. German.
-
Chemokine-induced recruitment of genetically modified bone marrow cells into the CNS of GM1-gangliosidosis mice corrects neuronal pathology.Blood. 2005 Oct 1;106(7):2259-68. doi: 10.1182/blood-2005-03-1189. Epub 2005 Jun 7. Blood. 2005. PMID: 15941905 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous